Ultrasound screening of ovarian cancer

References

[1] Bast Jr. RC. Molecular approaches to personalizing management of ovarian cancer. Ann Oncol. 2011;22(Suppl 8):viii5–15.10.1093/annonc/mdr516Search in Google Scholar

[2] Yang WL, Lu Z, Bast Jr. RC. The role of biomarkers in the management of epithelial ovarian cancer. Expert Rev Mol Diagn. 2017;17:577–91.10.1080/14737159.2017.1326820Search in Google Scholar

[3] Seidman JD, Russell P, Kurman RJ. Surface epithelial tumors of the ovary. In: Kurman RJ, editor. Blaustein’s pathology of the female genital tract, 5th ed. New York: Springer-Verlag; 2002. p. 791–904.Search in Google Scholar

[4] Vrabie CD, Petrescu A, Waller M, Dina I. Clinical factors and biomarkers in ovarian tumors development. Rom J Morphol Embryol. 2008;49:327–38.Search in Google Scholar

[5] Hoskins P, Gotlieb W. Ovarian cancer screening: UKCTOCS trial. Lancet. 2016;387:2602–603.10.1016/S0140-6736(16)30848-0Search in Google Scholar

[6] Beral V, Gaitskell K, Hermon C, Moser K, Reeves G, Collaborative Group on Epidemiological Studies of Ovarian Cancer, et al. Ovarian cancer and smoking: individual participant meta-analysis including 28,114 women with ovarian cancer from 51 epidemiological studies. Lancet Oncol. 2012;13:946–56.10.1016/S1470-2045(12)70322-4Search in Google Scholar

[7] Gallant D, Druckmann R, Kuhn W. Imagerie des tumeurs ovariennes, du bénin au malin: les signes d’appel. Genesis. 2017;193:6–11.Search in Google Scholar

[8] Campbell S, Bhan V, Royston P, Whitehead MI, Collins WP. Transabdominal ultrasound screening for early ovarian cancer. Br Med J. 1989;299:1363–7.10.1136/bmj.299.6712.1363Search in Google Scholar PubMed PubMed Central

[9] Bourne TH, Campbell S, Reynolds KM, Whitehead MI, Hampson J, Royston P, et al. Screening for early familial ovarian cancer with transvaginal ultrasonography and colour blood flow imaging. Br Med J. 1993;306:1025–9.10.1136/bmj.306.6884.1025Search in Google Scholar PubMed PubMed Central

[10] Kelsey TW, Dodwell SK, Wilkinson AG, Greve T, Andersen CY, Anderson RA, et al. Ovarian volume throughout life: a validated normative model. PLoS One. 2013;8.10.1371/journal.pone.0071465Search in Google Scholar PubMed PubMed Central

[11] Timmerman D, Testa AC, Bourne T, Ameye L, Jurkovic D, Van Holsbeke C, et al. Simple ultrasound-based rules for the diagnosis of ovarian cancer. Ultrasound Obstet Gynecol. 2008;31:681–90.10.1002/uog.5365Search in Google Scholar PubMed

[12] Timmerman D, Van Calster B, Testa A, Savelli L, Fischerova D, Froyman W, et al. Predicting the risk of malignancy in adnexal masses based on the Simple Rules from the International Ovarian Tumor Analysis group. Am J Obstet Gynecol. 2016;214:424–37.10.1016/j.ajog.2016.01.007Search in Google Scholar PubMed

[13] Blyuss O, Burnell M, Ryan A, Gentry-Maharaj A, Mariño IP, Kalsi J, et al. Comparison of longitudinal CA125 algorithms as a first-line screen for ovarian cancer in the general population. Clin Cancer Res. 2018;24:4726–33.10.1158/1078-0432.CCR-18-0208Search in Google Scholar PubMed PubMed Central

[14] Wright AA, Bohlke K, Armstrong DK, Bookman MA, Cliby WA, Coleman RL, et al. Neoadjuvant chemotherapy for newly diagnosed, advanced ovarian cancer: Society of Gynecologic Oncology and American Society of Clinical Oncology Clinical Practice Guideline. J Clin Oncol. 2016;34:3460–73.10.1200/JCO.2016.68.6907Search in Google Scholar

[15] Aletti GD, Dowdy SC, Podratz KC, Cliby WA. Relationship among surgical complexity, shortterm morbidity, and overall survival in primary surgery for advanced ovarian cancer. Am J Obstet Gynecol. 2007;197:676e671–7.10.1016/j.ajog.2007.10.495Search in Google Scholar

[16] Bast Jr. RC, Hennessy B, Mills GB. The biology of ovarian cancer: new opportunities for translation. Nat Rev Cancer. 2009;9:415–28.10.1038/nrc2644Search in Google Scholar

[17] Kurman RJ, Shih Ie M. The dualistic model of ovarian carcinogenesis: revisited, revised, and expanded. Am J Pathol. 2016;186:733–47.10.1016/j.ajpath.2015.11.011Search in Google Scholar

[18] Romero I, Bast Jr. RC. Minireview: human ovarian cancer: biology, current management, and paths to personalizing therapy. Endocrinology. 2012;153:1593–602.10.1210/en.2011-2123Search in Google Scholar

[19] Menon U, Gentry-Maharaj A, Hallett R, Ryan A, Burnell M, Sharma A, et al. Sensitivity and specificity of multimodal and ultrasound screening for ovarian cancer, and stage distribution of detected cancers: results of the prevalence screen of the UK Collaborative Trial of Ovarian Cancer Screening (UKCTOCS). Lancet Oncol. 2009;10:327–40.10.1016/S1470-2045(09)70026-9Search in Google Scholar

[20] van Nagell Jr. JR , DePriest PD, Ueland FR, DeSimone CP, Cooper AL, McDonald JM, et al. Ovarian cancer screening with annual transvaginal sonography: findings of 25,000 women screened. Cancer. 2007;109:1887–96.10.1002/cncr.22594Search in Google Scholar PubMed

[21] Buys SS, Partridge E, Black A, Johnson CC, Lamerato L, Isaacs C, et al. Effect of screening on ovarian cancer mortality: the Prostate, Lung, Colorectal and Ovarian (PLCO) Cancer Screening Randomized Controlled Trial. J Am Med Assoc. 2011;305:2295–303.10.1001/jama.2011.766Search in Google Scholar PubMed

[22] Pinsky PF, Yu K, Kramer BS, Black A, Buys SS, Partridge E, et al. Extended mortality results for ovarian cancer screening in the PLCO trial with median 15 years follow-up. Gynecol Oncol. 2016;143:270–5.10.1016/j.ygyno.2016.08.334Search in Google Scholar PubMed PubMed Central

[23] Henderson JT, Webber EM, Sawaya GF. Screening for ovarian cancer: updated evidence report and systematic review for the US Preventive Services Task Force. J Am Med Assoc. 2018;319:595–606.10.1001/jama.2017.21421Search in Google Scholar PubMed

[24] van Nagell Jr. JR, Burgess BT, Miller RW, Baldwin L, DeSimone CP, Ueland FR, et al. Survival of women with type I and II epithelial ovarian cancer detected by ultrasound screening. Obstet Gynecol. 2018;132:1091–100.10.1097/AOG.0000000000002921Search in Google Scholar PubMed

[25] Liu H, Xiang H, Mu R, Tuoerhan P, Zeng Q, Zhou H, et al. Value of transvaginal two-dimensional contrast-enhanced ultrasonography in diagnosing atypical ovarian corpus luteum hematoma. Biomed Res Int. 2018:3120579.10.1155/2018/3120579Search in Google Scholar PubMed PubMed Central

[26] Menon U, Ryan A, Kalsi J, Gentry-Maharaj A, Dawnay A, Habib M, et al. Risk algorithm using serial biomarker measurements doubles the number of screen-detected cancers compared with a single-threshold rule in the United Kingdom Collaborative Trial of Ovarian Cancer Screening. J Clin Oncol. 2015;33:2062–71.10.1200/JCO.2014.59.4945Search in Google Scholar PubMed PubMed Central

[27] Buys SS, Partridge E, Greene MH, Prorok PC, Reding D, Riley TL, et al. Ovarian cancer screening in the Prostate, Lung, Colorectal and Ovarian (PLCO) cancer screening trial: findings from the initial screen of a randomized trial. Am J Obstet Gynecol. 2005;193:1630–9.10.1016/j.ajog.2005.05.005Search in Google Scholar PubMed

[28] Jacobs IJ, Menon U, Ryan A, Gentry-Maharaj A, Burnell M, Kalsi JK, et al. Ovarian cancer screening and mortality in the UK Collaborative Trial of Ovarian Cancer Screening (UKCTOCS): a randomised controlled trial. Lancet. 2016;387:945–56.10.1158/1538-7445.AM2016-CT104Search in Google Scholar

[29] Froyman W, Wynants L, Landolfo C, Bourne T, Valentin L, Testa A, et al. Validation of the performance of International Ovarian Tumor Analysis (IOTA) methods in the diagnosis of early stage ovarian cancer in a non-screening population. Diagnostics (Basel). 2017;7. DOI: 10.3390/diagnostics7020032.Search in Google Scholar PubMed PubMed Central

[30] Lu KH, Skates S, Hernandez MA, Bedi D, Bevers T, Leeds L, et al. A 2-stage ovarian cancer screening strategy using the Risk of Ovarian Cancer Algorithm (ROCA) identifies early-stage incident cancers and demonstrates high positive predictive value. Cancer. 2013;119:3454–61.10.1002/cncr.28183Search in Google Scholar PubMed PubMed Central

[31] Menon U, McGuire AJ, Raikou M, Ryan A, Davies SK, Burnell M, et al. The cost-effectiveness of screening for ovarian cancer: results from the UK Collaborative Trial of Ovarian Cancer Screening (UKCTOCS). Br J Cancer. 2017;117:619–27.10.1038/bjc.2017.222Search in Google Scholar PubMed PubMed Central